<NOTICE>
      <PREAMB>
        <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
        <SUBAGY>Food and Drug Administration</SUBAGY>
        <DEPDOC>[Docket No. FDA-2012-N-0001]</DEPDOC>
        <SUBJECT>Blood Products Advisory Committee; Cancellation</SUBJECT>
        <AGY>
          <HD SOURCE="HED">AGENCY:</HD>
          <P>Food and Drug Administration, HHS.</P>
        </AGY>
        <ACT>
          <HD SOURCE="HED">ACTION:</HD>
          <P>Notice.</P>
        </ACT>
        <SUM>
          <HD SOURCE="HED">SUMMARY:</HD>

          <P>The meeting of the Blood Products Advisory Committee scheduled for February 29, 2012 is cancelled. This meeting was announced in the <E T="04">Federal Register</E> of January 30, 2012 (77 FR 4567). FDA intends to convene at a future date a public scientific workshop to discuss the evaluation of possible new plasma products manufactured following storage at room temperature for up to 24 hours.</P>
        </SUM>
        <FURINF>
          <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
          <P>Bryan Emery or Pearl Muckelvene, <PRTPAGE P="7589"/>Center for Biologics Evaluation and Research (HFM-71), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, Contact 1-301-827-1277 or 1-301-827-1281, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), and follow the prompts to the desired center or product area. Please call the Information Line for up-to-date information on this meeting.</P>
          <SIG>
            <DATED>Dated: February 7, 2012.</DATED>
            <NAME>Jill Hartzler Warner,</NAME>
            <TITLE>Acting Associate Commissioner for Special Medical Programs.</TITLE>
          </SIG>
        </FURINF>
      </PREAMB>
      <FRDOC>[FR Doc. 2012-3199 Filed 2-10-12; 8:45 am]</FRDOC>
      <BILCOD>BILLING CODE 4160-01-P</BILCOD>
    </NOTICE>